公开(公告)号：US20240358833A1

公开(公告)日：2024-10-31

申请号：US18682764

申请日：2022-08-09

Applicant: The Regents of the University of California

Inventor： Qizhi TANG ,  Yannick D. MULLER ,  Leonardo M.R. FERREIRA ,  Emilie RONIN ,  Johanna C. WAGNER ,  Yani PENG

IPC: A61K39/00 ,  A61P37/06 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K39/46434 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/4631 ,  A61P37/06 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0637 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/622 ,  C12N2510/00

Abstract: The present disclosure relates to chimeric-antigen-receptor regulatory T cells (CAR-Tregs) that include an exogenous nucleic acid encoding a chimeric antigen receptor (CAR) comprising the complementarity determining regions (CDRs) of a human anti-HLA-A2 antibody grafted onto an antibody scaffold, a hinge domain, a transmembrane domain; and an intracellular domain, where the CAR-Treg expresses the CAR on the cell surface. Vectors and methods of making and using such CAR-Tregs are disclosed as well.

公开(公告)号：US20240294648A1

公开(公告)日：2024-09-05

申请号：US18473695

申请日：2023-09-25

Applicant: The Johns Hopkins University

Inventor： Emily Han-Chung Hsiue ,  Qing Wang ,  Bert Vogelstein ,  Kenneth W. Kinzler ,  Shibin Zhou ,  Jacqueline Douglass ,  Michael S. Hwang ,  Nickolas Papadopoulos

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73

CPC classification number: C07K16/2833 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2809 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2319/03

Abstract: This document provides methods and materials for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.

公开(公告)号：US20240279344A1

公开(公告)日：2024-08-22

申请号：US18404536

申请日：2024-01-04

Applicant: CDR-LIFE AG

Inventor： Anna Maria Sobieraj ,  Fabian Bert Scheifele ,  Stephanie Jungmichel ,  Leonardo Borras ,  Christian Valdemar Vinge Leisner

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2833 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92

Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.

公开(公告)号：US20240279343A1

公开(公告)日：2024-08-22

申请号：US18351184

申请日：2023-07-12

Applicant: Gritstone bio, Inc.

Inventor： Isaac J. Rondon ,  Christine Janson ,  Manankumar Anilkumar Shah ,  Karin Jooss

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/46

CPC classification number: C07K16/2833 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are multispecific antigen binding proteins that selectively bind a particular KKLC-1 (CT-83) shared antigen and CD3, as well as related methods, kits, and compositions. Included herein are multispecific antigen binding proteins with a circularized conformation.

公开(公告)号：US12065477B2

公开(公告)日：2024-08-20

申请号：US17465426

申请日：2021-09-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko Schuster ,  Janet Peper ,  Kevin Roehle ,  Philipp Wagner ,  Hans-Georg Rammensee

IPC: A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/28 ,  C12Q1/6886 ,  G16B30/00

CPC classification number: C07K14/70539 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C07K16/2818 ,  C07K16/2833 ,  C12Q1/6886 ,  G16B30/00 ,  A61K39/00 ,  A61K2039/892 ,  C07K2317/34 ,  C12Q2600/156

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12060400B2

公开(公告)日：2024-08-13

申请号：US18161423

申请日：2023-01-30

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette Song ,  Franziska Hoffgaard ,  Daniel Johannes Kowalewski ,  Oliver Schoor ,  Jens Fritsche ,  Toni Weinschenk ,  Harpreet Singh

IPC: C07K14/47 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001186 ,  A61K39/001193 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C12N5/0636 ,  C12N15/115 ,  C07K2319/00 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12059458B2

公开(公告)日：2024-08-13

申请号：US17514599

申请日：2021-10-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Colette Song

IPC: A61K39/00 ,  A61K35/17 ,  A61P35/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  G16B25/00 ,  G16B25/10 ,  A61K35/12 ,  C07K14/705

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K39/001102 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3038 ,  C12N5/0636 ,  C12N15/115 ,  G16B25/00 ,  G16B25/10 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/705 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12049504B2

公开(公告)日：2024-07-30

申请号：US16648967

申请日：2018-09-19

Applicant: THE UNIVERSITY OF BRITISH COLUMBIA ,  CDRD VENTURES INC.

Inventor： Megan Levings ,  Paul Orban ,  Nicholas Dawson ,  Caroline Lamarche ,  Jan Peter Bergqvist

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/06 ,  C07K14/705 ,  C07K14/725

CPC classification number: C07K16/2833 ,  A61K35/17 ,  A61P37/06 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.

公开(公告)号：US20240247066A1

公开(公告)日：2024-07-25

申请号：US18560003

申请日：2022-05-11

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Kenan Christopher Garcia ,  Daisuke Nishimiya ,  Xinbo Yang

IPC: C07K16/28 ,  A61K38/00 ,  C07K14/725 ,  G01N33/68

CPC classification number: C07K16/2833 ,  C07K14/7051 ,  G01N33/6845 ,  A61K38/00 ,  C07K2317/622 ,  C07K2319/30

Abstract: Compositions and methods are provided for the development and screening of antibody-based binding regions (ABR) that mimic T cell receptor specificity (TCRm). The TCRm-ABR of the disclosure are developed to specifically bind to the combination of an MHC antigen and peptide, and to substantially lack binding to the MHC in the absence of the cognate antigen.

公开(公告)号：US20240228668A1

公开(公告)日：2024-07-11

申请号：US18547623

申请日：2022-02-28

Applicant: New York University

Inventor： Shohei KOIDE ,  Benjamin NEEL ,  Carmine FEDELE ,  Kai Wen TENG ,  Akiko KOIDE ,  Takamitsu HATTORI ,  Lorenzo MASO

IPC: C07K16/44 ,  A61K47/68 ,  C07K16/28

CPC classification number: C07K16/44 ,  A61K47/6849 ,  C07K16/2833 ,  C07K2317/56 ,  C07K2317/626

Abstract: Provided are compositions and methods that include binding partners that bind with specificity to target sites on proteins or peptides that comprise a covalently attached molecule. The binding partners are provided as antibodies and antibody derivatives that specifically bind to proteins and peptides that have been covalently modified by attachment of a molecule, such as a drug. The binding partners can bind with specificity to covalently modified peptides when presented in the context of a major histocompatibility complex (MHC). Uses of the compositions and methods for prophylaxis or therapy of disorders are also provided.